Global Coronavirus Vaccine Investment Market
Global Coronavirus Vaccine Investment Market

Coronavirus Vaccine Investment Comprehensive Study by Type (Government, Private Firms), Application (Hospitals, Research Laboratories, Clinics, Others) Players and Region - Global Market Outlook to 2025

Coronavirus Vaccine Investment Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Apr 2020 Edition 204 Pages 212 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study

The coronavirus (COVID-19) disease is affecting 210 countries and territories around the world and 2 international conveyances. The major players are investing in the research and development activities of the coronavirus vaccine. In the race to develop a vaccine to end the COVID-19 pandemic, governments, charities and Big Pharma firms are sinking billions of dollars into bets with extraordinarily low odds of success. They are ensuring quick development of new coronavirus vaccine as well as it is ready to distribute as soon as it's approved. In the United States, the Biomedical Advanced Research and Development Authority (BARDA), a federal agency that funds disease-fighting technology, has recently announced that it invests billions to support coronavirus vaccine development and the scale-up of manufacturing for promising candidates.

The market study is being classified by Type (Government and Private Firms), by Application (Hospitals, Research Laboratories, Clinics and Others) and major geographies with country level break-up.

Serum Institute of India (India), BioNTech SE (Germany), Pfizer Inc. (United States), Gilead Sciences Inc. (United States), GlaxoSmithKline (United States), Roche Holding AG (Switzerland), Inovio Pharmaceuticals, Inc. (United States), Moderna Inc. (United States), Novavax Inc. (United States) and AbbVie Inc. (United States) are some of the key players profiled in the study.

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Coronavirus Vaccine Investment market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Coronavirus Vaccine Investment market by Type, Application and Region.

On the basis of geography, the market of Coronavirus Vaccine Investment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Number of People Affecting the Coronavirus Disease Worldwide
  • Spread of Coronavirus Disease Worldwide
  • Government Initiatives and Support for Vaccine Development

Market Trend
  • High Demand for Total Cure of Coronavirus Total Cure Treatment

Restraints
  • Unavailability of Government Approved Vaccines in the Market

Opportunities
  • Huge Investment by Major Players for Coronavirus Vaccine Development
  • Rising Demand from End-users
  • High Future Demand for Vaccine from the Market

Challenges
  • Huge Investment for Research and Development of Coronavirus Vaccine


Recently Serum Institute of India, the world's largest vaccine maker announced that it is producing 40 million units of a coronavirus vaccine on trial in Oxford, without yet knowing if it works.


Key Target Audience
Coronavirus Vaccine Manufacturers, Distributors, Research Professionals, Emerging Companies and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Government
  • Private Firms
By Application
  • Hospitals
  • Research Laboratories
  • Clinics
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of People Affecting the Coronavirus Disease Worldwide
      • 3.2.2. Spread of Coronavirus Disease Worldwide
      • 3.2.3. Government Initiatives and Support for Vaccine Development
    • 3.3. Market Challenges
      • 3.3.1. Huge Investment for Research and Development of Coronavirus Vaccine
    • 3.4. Market Trends
      • 3.4.1. High Demand for Total Cure of Coronavirus Total Cure Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Coronavirus Vaccine Investment, by Type, Application and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Coronavirus Vaccine Investment (Value)
      • 5.2.1. Global Coronavirus Vaccine Investment by: Type (Value)
        • 5.2.1.1. Government
        • 5.2.1.2. Private Firms
      • 5.2.2. Global Coronavirus Vaccine Investment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Research Laboratories
        • 5.2.2.3. Clinics
        • 5.2.2.4. Others
      • 5.2.3. Global Coronavirus Vaccine Investment Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Coronavirus Vaccine Investment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Serum Institute of India (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. BioNTech SE (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Gilead Sciences Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Roche Holding AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Inovio Pharmaceuticals, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Moderna Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novavax Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AbbVie Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Coronavirus Vaccine Investment Sale, by Type, Application and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Coronavirus Vaccine Investment (Value)
      • 7.2.1. Global Coronavirus Vaccine Investment by: Type (Value)
        • 7.2.1.1. Government
        • 7.2.1.2. Private Firms
      • 7.2.2. Global Coronavirus Vaccine Investment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Research Laboratories
        • 7.2.2.3. Clinics
        • 7.2.2.4. Others
      • 7.2.3. Global Coronavirus Vaccine Investment Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Coronavirus Vaccine Investment: by Type(USD Million)
  • Table 2. Coronavirus Vaccine Investment Government , by Region USD Million (2014-2019)
  • Table 3. Coronavirus Vaccine Investment Private Firms , by Region USD Million (2014-2019)
  • Table 4. Coronavirus Vaccine Investment: by Application(USD Million)
  • Table 5. Coronavirus Vaccine Investment Hospitals , by Region USD Million (2014-2019)
  • Table 6. Coronavirus Vaccine Investment Research Laboratories , by Region USD Million (2014-2019)
  • Table 7. Coronavirus Vaccine Investment Clinics , by Region USD Million (2014-2019)
  • Table 8. Coronavirus Vaccine Investment Others , by Region USD Million (2014-2019)
  • Table 9. South America Coronavirus Vaccine Investment, by Country USD Million (2014-2019)
  • Table 10. South America Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 11. South America Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 12. Brazil Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 13. Brazil Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 14. Argentina Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 15. Argentina Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 16. Rest of South America Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 17. Rest of South America Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 18. Asia Pacific Coronavirus Vaccine Investment, by Country USD Million (2014-2019)
  • Table 19. Asia Pacific Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 20. Asia Pacific Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 21. China Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 22. China Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 23. Japan Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 24. Japan Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 25. India Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 26. India Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 27. South Korea Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 28. South Korea Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 29. Taiwan Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 30. Taiwan Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 31. Australia Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 32. Australia Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 33. Rest of Asia-Pacific Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 34. Rest of Asia-Pacific Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 35. Europe Coronavirus Vaccine Investment, by Country USD Million (2014-2019)
  • Table 36. Europe Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 37. Europe Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 38. Germany Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 39. Germany Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 40. France Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 41. France Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 42. Italy Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 43. Italy Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 44. United Kingdom Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 45. United Kingdom Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 46. Netherlands Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 47. Netherlands Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 48. Rest of Europe Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 49. Rest of Europe Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 50. MEA Coronavirus Vaccine Investment, by Country USD Million (2014-2019)
  • Table 51. MEA Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 52. MEA Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 53. Middle East Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 54. Middle East Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 55. Africa Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 56. Africa Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 57. North America Coronavirus Vaccine Investment, by Country USD Million (2014-2019)
  • Table 58. North America Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 59. North America Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 60. United States Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 61. United States Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 62. Canada Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 63. Canada Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 64. Mexico Coronavirus Vaccine Investment, by Type USD Million (2014-2019)
  • Table 65. Mexico Coronavirus Vaccine Investment, by Application USD Million (2014-2019)
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Coronavirus Vaccine Investment: by Type(USD Million)
  • Table 77. Coronavirus Vaccine Investment Government , by Region USD Million (2020-2025)
  • Table 78. Coronavirus Vaccine Investment Private Firms , by Region USD Million (2020-2025)
  • Table 79. Coronavirus Vaccine Investment: by Application(USD Million)
  • Table 80. Coronavirus Vaccine Investment Hospitals , by Region USD Million (2020-2025)
  • Table 81. Coronavirus Vaccine Investment Research Laboratories , by Region USD Million (2020-2025)
  • Table 82. Coronavirus Vaccine Investment Clinics , by Region USD Million (2020-2025)
  • Table 83. Coronavirus Vaccine Investment Others , by Region USD Million (2020-2025)
  • Table 84. South America Coronavirus Vaccine Investment, by Country USD Million (2020-2025)
  • Table 85. South America Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 86. South America Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 87. Brazil Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 88. Brazil Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 89. Argentina Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 90. Argentina Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 91. Rest of South America Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 92. Rest of South America Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 93. Asia Pacific Coronavirus Vaccine Investment, by Country USD Million (2020-2025)
  • Table 94. Asia Pacific Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 95. Asia Pacific Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 96. China Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 97. China Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 98. Japan Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 99. Japan Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 100. India Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 101. India Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 102. South Korea Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 103. South Korea Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 104. Taiwan Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 105. Taiwan Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 106. Australia Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 107. Australia Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 108. Rest of Asia-Pacific Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 109. Rest of Asia-Pacific Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 110. Europe Coronavirus Vaccine Investment, by Country USD Million (2020-2025)
  • Table 111. Europe Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 112. Europe Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 113. Germany Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 114. Germany Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 115. France Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 116. France Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 117. Italy Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 118. Italy Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 119. United Kingdom Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 120. United Kingdom Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 121. Netherlands Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 122. Netherlands Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 123. Rest of Europe Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 124. Rest of Europe Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 125. MEA Coronavirus Vaccine Investment, by Country USD Million (2020-2025)
  • Table 126. MEA Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 127. MEA Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 128. Middle East Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 129. Middle East Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 130. Africa Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 131. Africa Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 132. North America Coronavirus Vaccine Investment, by Country USD Million (2020-2025)
  • Table 133. North America Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 134. North America Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 135. United States Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 136. United States Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 137. Canada Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 138. Canada Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 139. Mexico Coronavirus Vaccine Investment, by Type USD Million (2020-2025)
  • Table 140. Mexico Coronavirus Vaccine Investment, by Application USD Million (2020-2025)
  • Table 141. Research Programs/Design for This Report
  • Table 142. Key Data Information from Secondary Sources
  • Table 143. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Coronavirus Vaccine Investment: by Type USD Million (2014-2019)
  • Figure 5. Global Coronavirus Vaccine Investment: by Application USD Million (2014-2019)
  • Figure 6. South America Coronavirus Vaccine Investment Share (%), by Country
  • Figure 7. Asia Pacific Coronavirus Vaccine Investment Share (%), by Country
  • Figure 8. Europe Coronavirus Vaccine Investment Share (%), by Country
  • Figure 9. MEA Coronavirus Vaccine Investment Share (%), by Country
  • Figure 10. North America Coronavirus Vaccine Investment Share (%), by Country
  • Figure 11. Global Coronavirus Vaccine Investment share by Players 2019 (%)
  • Figure 12. Global Coronavirus Vaccine Investment share by Players (Top 3) 2019(%)
  • Figure 13. Global Coronavirus Vaccine Investment share by Players (Top 5) 2019(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Serum Institute of India (India) Revenue, Net Income and Gross profit
  • Figure 16. Serum Institute of India (India) Revenue: by Geography 2019
  • Figure 17. BioNTech SE (Germany) Revenue, Net Income and Gross profit
  • Figure 18. BioNTech SE (Germany) Revenue: by Geography 2019
  • Figure 19. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer Inc. (United States) Revenue: by Geography 2019
  • Figure 21. Gilead Sciences Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Gilead Sciences Inc. (United States) Revenue: by Geography 2019
  • Figure 23. GlaxoSmithKline (United States) Revenue, Net Income and Gross profit
  • Figure 24. GlaxoSmithKline (United States) Revenue: by Geography 2019
  • Figure 25. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Roche Holding AG (Switzerland) Revenue: by Geography 2019
  • Figure 27. Inovio Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Inovio Pharmaceuticals, Inc. (United States) Revenue: by Geography 2019
  • Figure 29. Moderna Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Moderna Inc. (United States) Revenue: by Geography 2019
  • Figure 31. Novavax Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Novavax Inc. (United States) Revenue: by Geography 2019
  • Figure 33. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. AbbVie Inc. (United States) Revenue: by Geography 2019
  • Figure 35. Global Coronavirus Vaccine Investment: by Type USD Million (2020-2025)
  • Figure 36. Global Coronavirus Vaccine Investment: by Application USD Million (2020-2025)
  • Figure 37. South America Coronavirus Vaccine Investment Share (%), by Country
  • Figure 38. Asia Pacific Coronavirus Vaccine Investment Share (%), by Country
  • Figure 39. Europe Coronavirus Vaccine Investment Share (%), by Country
  • Figure 40. MEA Coronavirus Vaccine Investment Share (%), by Country
  • Figure 41. North America Coronavirus Vaccine Investment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Serum Institute of India (India)
  • BioNTech SE (Germany)
  • Pfizer Inc. (United States)
  • Gilead Sciences Inc. (United States)
  • GlaxoSmithKline (United States)
  • Roche Holding AG (Switzerland)
  • Inovio Pharmaceuticals, Inc. (United States)
  • Moderna Inc. (United States)
  • Novavax Inc. (United States)
  • AbbVie Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation